Surveillance for Pancreatic Cancer in High-Risk Individuals Leads to Improved Outcomes : A Propensity Score-Matched Analysis
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved..
BACKGROUND & AIMS: Recent pancreatic cancer surveillance programs of high-risk individuals have reported improved outcomes. This study assessed to what extent outcomes of pancreatic ductal adenocarcinoma (PDAC) in patients with a CDKN2A/p16 pathogenic variant diagnosed under surveillance are better as compared with patients with PDAC diagnosed outside surveillance.
METHODS: In a propensity score matched cohort using data from the Netherlands Cancer Registry, we compared resectability, stage, and survival between patients diagnosed under surveillance with non-surveillance patients with PDAC. Survival analyses were adjusted for potential effects of lead time.
RESULTS: Between January 2000 and December 2020, 43,762 patients with PDAC were identified from the Netherlands Cancer Registry. Thirty-one patients with PDAC under surveillance were matched in a 1:5 ratio with 155 non-surveillance patients based on age at diagnosis, sex, year of diagnosis, and tumor location. Outside surveillance, 5.8% of the patients had stage I cancer, as compared with 38.7% of surveillance patients with PDAC (odds ratio [OR], 0.09; 95% confidence interval [CI], 0.04-0.19). In total, 18.7% of non-surveillance patients vs 71.0% of surveillance patients underwent a surgical resection (OR, 10.62; 95% CI, 4.56-26.63). Patients in surveillance had a better prognosis, reflected by a 5-year survival of 32.4% and a median overall survival of 26.8 months vs 4.3% 5-year survival and 5.2 months median overall survival in non-surveillance patients (hazard ratio, 0.31; 95% CI 0.19-0.50). For all adjusted lead times, survival remained significantly longer in surveillance patients than in non-surveillance patients.
CONCLUSION: Surveillance for PDAC in carriers of a CDKN2A/p16 pathogenic variant results in earlier detection, increased resectability, and improved survival as compared with non-surveillance patients with PDAC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:164 |
|---|---|
| Enthalten in: |
Gastroenterology - 164(2023), 7 vom: 28. Juni, Seite 1223-1231.e4 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Klatte, Derk C F [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
High-Risk Individual |
|---|
| Anmerkungen: |
Date Completed 23.05.2023 Date Revised 13.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1053/j.gastro.2023.02.032 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353952761 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353952761 | ||
| 003 | DE-627 | ||
| 005 | 20231227131141.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1053/j.gastro.2023.02.032 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1225.xml |
| 035 | |a (DE-627)NLM353952761 | ||
| 035 | |a (NLM)36889551 | ||
| 035 | |a (PII)S0016-5085(23)00218-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Klatte, Derk C F |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Surveillance for Pancreatic Cancer in High-Risk Individuals Leads to Improved Outcomes |b A Propensity Score-Matched Analysis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.05.2023 | ||
| 500 | |a Date Revised 13.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND & AIMS: Recent pancreatic cancer surveillance programs of high-risk individuals have reported improved outcomes. This study assessed to what extent outcomes of pancreatic ductal adenocarcinoma (PDAC) in patients with a CDKN2A/p16 pathogenic variant diagnosed under surveillance are better as compared with patients with PDAC diagnosed outside surveillance | ||
| 520 | |a METHODS: In a propensity score matched cohort using data from the Netherlands Cancer Registry, we compared resectability, stage, and survival between patients diagnosed under surveillance with non-surveillance patients with PDAC. Survival analyses were adjusted for potential effects of lead time | ||
| 520 | |a RESULTS: Between January 2000 and December 2020, 43,762 patients with PDAC were identified from the Netherlands Cancer Registry. Thirty-one patients with PDAC under surveillance were matched in a 1:5 ratio with 155 non-surveillance patients based on age at diagnosis, sex, year of diagnosis, and tumor location. Outside surveillance, 5.8% of the patients had stage I cancer, as compared with 38.7% of surveillance patients with PDAC (odds ratio [OR], 0.09; 95% confidence interval [CI], 0.04-0.19). In total, 18.7% of non-surveillance patients vs 71.0% of surveillance patients underwent a surgical resection (OR, 10.62; 95% CI, 4.56-26.63). Patients in surveillance had a better prognosis, reflected by a 5-year survival of 32.4% and a median overall survival of 26.8 months vs 4.3% 5-year survival and 5.2 months median overall survival in non-surveillance patients (hazard ratio, 0.31; 95% CI 0.19-0.50). For all adjusted lead times, survival remained significantly longer in surveillance patients than in non-surveillance patients | ||
| 520 | |a CONCLUSION: Surveillance for PDAC in carriers of a CDKN2A/p16 pathogenic variant results in earlier detection, increased resectability, and improved survival as compared with non-surveillance patients with PDAC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a High-Risk Individual | |
| 650 | 4 | |a Pancreatic Cancer | |
| 650 | 4 | |a Surveillance | |
| 650 | 4 | |a Survival | |
| 700 | 1 | |a Boekestijn, Bas |e verfasserin |4 aut | |
| 700 | 1 | |a Onnekink, Anke M |e verfasserin |4 aut | |
| 700 | 1 | |a Dekker, Friedo W |e verfasserin |4 aut | |
| 700 | 1 | |a van der Geest, Lydia G |e verfasserin |4 aut | |
| 700 | 1 | |a Wasser, Martin N J M |e verfasserin |4 aut | |
| 700 | 1 | |a Feshtali, Shirin |e verfasserin |4 aut | |
| 700 | 1 | |a Mieog, J Sven D |e verfasserin |4 aut | |
| 700 | 1 | |a Luelmo, Saskia A C |e verfasserin |4 aut | |
| 700 | 1 | |a Morreau, Hans |e verfasserin |4 aut | |
| 700 | 1 | |a Potjer, Thomas P |e verfasserin |4 aut | |
| 700 | 1 | |a Inderson, Akin |e verfasserin |4 aut | |
| 700 | 1 | |a Boonstra, Jurjen J |e verfasserin |4 aut | |
| 700 | 1 | |a Vasen, Hans F A |e verfasserin |4 aut | |
| 700 | 1 | |a van Hooft, Jeanin E |e verfasserin |4 aut | |
| 700 | 1 | |a Bonsing, Bert A |e verfasserin |4 aut | |
| 700 | 1 | |a van Leerdam, Monique E |e verfasserin |4 aut | |
| 700 | 0 | |a Dutch Pancreatic Cancer Group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Gastroenterology |d 1945 |g 164(2023), 7 vom: 28. Juni, Seite 1223-1231.e4 |w (DE-627)NLM00001706X |x 1528-0012 |7 nnns |
| 773 | 1 | 8 | |g volume:164 |g year:2023 |g number:7 |g day:28 |g month:06 |g pages:1223-1231.e4 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1053/j.gastro.2023.02.032 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 164 |j 2023 |e 7 |b 28 |c 06 |h 1223-1231.e4 | ||